Treatment with D-penicillamine Improves Dopamine D2-Receptor Binding and T2-Signal Intensity in de novo Wilson's Disease
Neurol 44:1079-1082, Schwarz,J.,et al, 1994
Wilson's Disease, Development of Neurological Disease after Beginning Penicillamine Therapy
Arch Neurol 47:595-596, Glass,J.D.,et al, 1990
Wilson Disease: Description of 282 Patients Evaluated Over 3 Decades
Medicine 86:112-121, Taly,A.B., et al, 2007
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Wilson Disease
Medicine 71:139-164, Brewer,G.J.&Yuzbasiyan-Gurkan,V., 1992
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
Penicillamine-Induced Myositis
Am J Med 77:719-722, Halla,J.T.,et al, 1984
Penicillamine-associated Myasthenia Gravis
Neurol 30:1246-1250, Albers,J.W.,et al, 1980
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979
Reversible Forms of Motor Neuron-Disease:Lead"Neuropathy"
Neurol 22:446, Boothby,J., 1972